UGent and UZ Gent (gmp-unit.be), has received an important grant of €790K from ‘the Stichting Tegen Kanker’ and ‘Kom op tegen Kanker’, both Belgians associations funding research to improve cancer outcome. The grant will be used to setup a Phase I clinical trial of Galsome-NEO, a personalized neo-antigen targeted mRNA vaccine in patiens with advanced unresectable PD-L1 negative non-small cell lung cancer. The Galsome-NEO trial is executed in collaboration with Ghent Research Group on Nanomedicines (Prof Stefaan De Smedt, Dr ine Lentacker and Dr. Rein Verbeke), Center for Medical Genetics (prof Björn Menten) and de Department of Lung Diseases (prof Karim Vermaelen, prof Dieter Stevens).
Nanomedicine Centre 